Bayer : Bayer increases sales and EBITDA before special items in the third quarter, improves full-year outlook

Bayer is operationally on track to deliver its full-year commitments at the nine-month mark, while also aiming to capitalize on improved trends as the year draws to a close. "We've reached a turning point in Pharma's growth trajectory and we're beginning to see the other side," CEO Bill Anderson sai...